Literature DB >> 11753613

Forced expression of the Wilms tumor 1 (WT1) gene inhibits proliferation of human hematopoietic CD34(+) progenitor cells.

H Svedberg1, J Richter, U Gullberg.   

Abstract

The Wilms tumor gene (WT1) encodes a zinc-finger containing transcription factor present in primitive hematopoietic progenitor cells. WT1 is also highly expressed in most cases of acute myeloid leukemia. Moreover, WT1 can interfere with induced differentiation of leukemic cell lines. These data suggest a function of WT1 in the maintenance of a primitive phenotype and a role in leukemogenesis by interfering with differentiation, prompting us to investigate its function in human hematopoietic progenitor cells. By retroviral transfer, human CD34(+) cord blood progenitor cells were transduced with a vector encoding either of two splicing variants of WT1, with or without the KTS insert in the zinc-finger domain, linked to expression of green fluorescent protein (GFP) via an internal ribosomal entry site. When compared to cells transduced with vector containing GFP only, WT1 expressing cells showed strongly reduced colony formation in methylcellulose and inhibited proliferation in suspension culture, with no apparent reduction in viability. Cell cycle phase distribution was not affected by WT1 expression. No signs of impaired differentiation, as judged by the surface markers CD11b, CD14 and glycophorin were detected. In contrast to the results with human CD34(+) progenitor cells, the proliferation of murine bone marrow cells was not significantly affected by WT1, consistent with previous data. We conclude that forced expression of WT1 in highly enriched human hematopoietic progenitor cells leads to strong anti-proliferative effects but is compatible with induced maturation of these cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11753613     DOI: 10.1038/sj.leu.2402303

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  10 in total

1.  Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.

Authors:  Sandra Heesch; Nicola Goekbuget; Andrea Stroux; Jutta Ortiz Tanchez; Cornelia Schlee; Thomas Burmeister; Stefan Schwartz; Olga Blau; Ulrich Keilholz; Antonia Busse; Dieter Hoelzer; Eckhard Thiel; Wolf-Karsten Hofmann; Claudia D Baldus
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

2.  Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation.

Authors:  Maike Busch; Heinrich Schwindt; Artur Brandt; Manfred Beier; Nicole Görldt; Paul Romaniuk; Eneda Toska; Stefan Roberts; Hans-Dieter Royer; Brigitte Royer-Pokora
Journal:  Hum Mol Genet       Date:  2014-03-11       Impact factor: 6.150

Review 3.  Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.

Authors:  Vicki Huff
Journal:  Nat Rev Cancer       Date:  2011-01-20       Impact factor: 60.716

4.  Central role of PI3K in transcriptional activation of hTERT in HTLV-I-infected cells.

Authors:  Marcia Bellon; Christophe Nicot
Journal:  Blood       Date:  2008-05-29       Impact factor: 22.113

Review 5.  Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia.

Authors:  Raajit Rampal; Maria E Figueroa
Journal:  Haematologica       Date:  2016-06       Impact factor: 9.941

Review 6.  The role of WT1 in oncogenesis: tumor suppressor or oncogene?

Authors:  David M Loeb; Saraswati Sukumar
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.

Authors:  Qiu-Sha Huang; Jing-Zhi Wang; Ya-Zhen Qin; Qiao-Zhu Zeng; Qian Jiang; Hao Jiang; Jin Lu; Hui-Xin Liu; Yi Liu; Jing-Bo Wang; Li Su; Hong-Yu Zhang; Zhen-Ling Li; Su-Jun Gao; Bo Huang; Yu-Ying Liu; Yan-Rong Liu; Lan-Ping Xu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Blood Adv       Date:  2019-11-12

8.  Prognostic significance of specific anti-WT1 IgG antibody level in plasma in patients with ovarian carcinoma.

Authors:  Charlotta Andersson; Yusuke Oji; Nina Ohlson; Sihan Wang; Xingru Li; Ulrika Ottander; Eva Lundin; Haruo Sugiyama; Aihong Li
Journal:  Cancer Med       Date:  2014-04-08       Impact factor: 4.452

9.  WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.

Authors:  Giorgia Montano; Karina Vidovic; Chiara Palladino; Elena Cesaro; Gaetano Sodaro; Concetta Quintarelli; Biagio De Angelis; Santa Errichiello; Fabrizio Pane; Paola Izzo; Michela Grosso; Urban Gullberg; Paola Costanzo
Journal:  Oncotarget       Date:  2015-09-29

10.  The transcriptional coregulator NAB2 is a target gene for the Wilms' tumor gene 1 protein (WT1) in leukemic cells.

Authors:  Helena Jernmark Nilsson; Giorgia Montano; Tove Ullmark; Andreas Lennartsson; Kristina Drott; Linnea Järvstråt; Björn Nilsson; Karina Vidovic; Urban Gullberg
Journal:  Oncotarget       Date:  2017-08-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.